DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients

Information source: M.D. Anderson Cancer Center
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Amenorrhea; Premature Ovarian Failure; Ovarian Function Insufficiency

Intervention: Leuprolide Acetate (Drug); Questionnaire (Behavioral); Hematopoietic Stem Cell Transplantation (Procedure)

Phase: Phase 2

Status: Completed

Sponsored by: M.D. Anderson Cancer Center

Official(s) and/or principal investigator(s):
Naoto Ueno, MD, PhD, Principal Investigator, Affiliation: M.D. Anderson Cancer Center


Primary Objectives:

- To determine the effectiveness of the 3-month depot leuprolide in inducing and

maintaining secondary amenorrhea in patients undergo hematopoietic stem cell transplantation.

- To determine the incidence of regained ovarian function manifested as spontaneous

restoration of menstruation and normalization of hormonal level in patients after transplantation and discontinuation of long-acting leuprolide.

Clinical Details

Official title: Phase II Study of GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients

Study design: Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Number of Participants With Secondary Amenorrhea Following 3-month Depot Leuprolide

Detailed description: All participants in this study will be scheduled for hematopoietic stem cell transplantation at The University of Texas (UT) MD Anderson Cancer Center. Within two months before the transplantation, all participants will have a medical history, physical exam, and blood tests for ovarian function and platelet count. Participants will also need to have a gynecologic exam within one year before the transplantation. Participants who are eligible will receive the first dose of leuprolide as an injection into either the shoulder muscle or the thigh muscle during their first clinic visit. Participants who have low platelet count will be given platelet transfusion before the injection. Participants will then go on to have the transplantation as scheduled. Three months after the first dose of injection participants will have another clinic visit where blood tests for ovarian function will be performed. A second dose of the leuprolide will be given as an injection into the muscle at this visit. Again, if patients have low platelet count at that time, platelet transfusion will be given to patients before the injection. Participants will be given a checklist sheet for them to record any side effects while on the effect of leuprolide. Three months after the last dose of the injection, patients will have the option to start taking or to resume oral contraceptive pills. Those who choose not to take or to resume oral contraceptive pills will be followed and observed for the return of menstrual or monthly cycles. Those who choose to take or to resume oral contraceptive pills, has to stop taking oral contraceptive pills for a period of 3-6 months starting 1 year after transplantation for us to assess the ovarian function. During the period of follow up and observation of the return of menstruation, participants will be seen every two months either in the clinic or in the hospital if they are admitted. Participants will fill out questionnaires about their menstrual history at these visits. They should take about 15 minutes to complete. Blood tests for the ovarian function will also be done during these visits. This is an investigational study. The drug used in this study is commercially available and has been approved by FDA for use in prostate cancer patients. Its use in this study is investigational. About seventy-five patients will take part in this study. All will be enrolled at MD Anderson.


Minimum age: N/A. Maximum age: 40 Years. Gender(s): Female.


Inclusion Criteria:

- Hematopoietic stem cell transplantation candidate.

- Post-menarche female less than 40 years old.

- Premenopausal before the start of transplantation, or the start of oral contraceptive


- Follicle-stimulating hormone (FSH) less than or equal to 20 IU/L and Luteinizing

hormone (LH) less than or equal to 20 IU/L within 1 weeks of initiation of injection or the ovarian status is determined by Gynecology Oncology Service.

- Agree to stop any oral contraceptive pills for a period of 3-6 months starting 1 year

post-transplant Exclusion Criteria:

- Breast cancer

- Ovarian cancer

- Pregnancy

- Hypersensitivity to any Gonadotropin-releasing hormone (GnRH) analogs

Locations and Contacts

UT MD Anderson Cancer Center, Houston, Texas 77030, United States
Additional Information

The University of Texas (UT) MD Anderson Cancer Center official website

Starting date: November 2002
Last updated: May 20, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017